Loading...
Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Brookie Best

    TitleTeacher
    SchoolUniversity of California, San Diego
    Address9500 Gilman Drive #0657
    CA La Jolla 92093
    Phone858-822-5550
    vCardDownload vCard

      Collapse Overview 
      Collapse Overview
      Dr. Brookie Best is a Professor of Clinical Pharmacy and Pediatrics and the Associate Dean for Admissions and Outreach at the University of California (UC), San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences (SSPPS) and the Department of Pediatrics, School of Medicine (SOM). She completed a Bachelor of Science degree at UC San Diego in Chemistry with an Emphasis in Chemical Education in 1994. She received her Pharm.D. degree in 1999 from UC San Francisco, and did her residency in Pharmacy Practice at the UC San Diego Medical Center in 2000. Dr. Best was an NICHD/NIH Fellowship recipient in Pediatric Clinical Pharmacology Research from 2001 to 2004, and completed a Masters of Advanced Studies (M.A.S.) in Clinical Research at UC San Diego in 2007. Dr. Best specializes in pharmacokinetics - the processes by which a drug is absorbed, distributed, metabolized and eliminated by the body - and maternal/fetal and pediatric clinical pharmacology research. Her research efforts have focused on studying anti-HIV drugs in pregnant women, children and non-pregnant adults. She also studies drugs used to treat Kawasaki disease, the leading cause of acquired heart disease in children.


      Collapse Research 
      Collapse Research Activities and Funding
      Developmental and Translational Pharmacology of Pediatric Antimicrobial Therapy
      NIH/NICHD U54HD071600Sep 26, 2011 - Jun 30, 2016
      Role: Co-Investigator
      Predoctoral Research Training in Maternal and Pediatric Pharmacology
      NIH/NICHD T35HD064385Apr 1, 2010 - Jul 31, 2022
      Role: Principal Investigator
      PEDIATRIC CLINICAL RESEARCH PHARMACOLOGY FELLOWSHIP
      NIH/NICHD F32HD008722Apr 1, 2001
      Role: Principal Investigator

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Brandl K, Adler D, Kelly C, Taylor P, Best B. Effect of a Dedicated Pharmacy Student Summer Research Program on Publication Rate. Am J Pharm Educ. 2017 Apr; 81(3):48. PMID: 28496268.
        View in: PubMed
      2. Melvin AJ, Montepiedra G, Aaron L, Meyer WA, Spiegel HM, Borkowsky W, Abzug MJ, Best B, Crain MJ, Borum PR, Graham B, Anthony P, Shin K, Siberry GK. Safety and Efficacy of Atorvastatin in Human Immunodeficiency Virus-infected Children, Adolescents and Young Adults With Hyperlipidemia. Pediatr Infect Dis J. 2017 Jan; 36(1):53-60. PMID: 27749649.
        View in: PubMed
      3. Mulligan N, Schalkwijk S, Best B, Colbers A, Wang J, Capparelli EV, Moltó J, Stek AM, Taylor G, Smith E, Hidalgo Tenorio C, Chakhtoura N, van Kasteren M, Fletcher CV, Mirochnick M, Burger D. Etravirine Pharmacokinetics in HIV-Infected Pregnant Women. Front Pharmacol. 2016; 7:239. PMID: 27540363; PMCID: PMC4972814.
      4. Tran AH, Best B, Stek A, Wang J, Capparelli EV, Burchett SK, Kreitchmann R, Rungruengthanakit K, George K, Cressey TR, Chakhtoura N, Smith E, Shapiro DE, Mirochnick M. Pharmacokinetics of Rilpivirine in HIV-Infected Pregnant Women. J Acquir Immune Defic Syndr. 2016 Jul 01; 72(3):289-96. PMID: 26918544; PMCID: PMC4911231 [Available on 07/01/17].
      5. Tremoulet AH, Jain S, Kim S, Newburger J, Arditi M, Franco A, Best B, Burns JC. Rationale and study design for a phase I/IIa trial of anakinra in children with Kawasaki disease and early coronary artery abnormalities (the ANAKID trial). Contemp Clin Trials. 2016 May; 48:70-5. PMID: 27080929.
        View in: PubMed
      6. Stek A, Best B, Wang J, Capparelli EV, Burchett SK, Kreitchmann R, Rungruengthanakit K, Cressey TR, Mofenson LM, Smith E, Shapiro D, Mirochnick M. Pharmacokinetics of Once Versus Twice Daily Darunavir in Pregnant HIV-Infected Women. J Acquir Immune Defic Syndr. 2015 Sep 01; 70(1):33-41. PMID: 25950206; PMCID: PMC4579345.
      7. Colbers A, Best B, Schalkwijk S, Wang J, Stek A, Hidalgo Tenorio C, Hawkins D, Taylor G, Kreitchmann R, Burchett S, Haberl A, Kabeya K, van Kasteren M, Smith E, Capparelli E, Burger D, Mirochnick M. Maraviroc Pharmacokinetics in HIV-1-Infected Pregnant Women. Clin Infect Dis. 2015 Nov 15; 61(10):1582-9. PMID: 26202768; PMCID: PMC4614410 [Available on 11/15/16].
      8. Watts DH, Stek A, Best B, Wang J, Capparelli EV, Cressey TR, Aweeka F, Lizak P, Kreitchmann R, Burchett SK, Shapiro DE, Hawkins E, Smith E, Mirochnick M. Raltegravir pharmacokinetics during pregnancy. J Acquir Immune Defic Syndr. 2014 Dec 01; 67(4):375-81. PMID: 25162818; PMCID: PMC4213295.
      9. McCormack SA, Best B. Protecting the fetus against HIV infection: a systematic review of placental transfer of antiretrovirals. Clin Pharmacokinet. 2014 Nov; 53(11):989-1004. PMID: 25223699; PMCID: PMC4214885.
      10. Elder NM, Atayee RS, Best B, Ma JD. Response to urine drug testing for oxycodone and its metabolites as a tool for drug-drug interactions. J Anal Toxicol. 2015 Jan-Feb; 39(1):80. PMID: 25288719.
        View in: PubMed
      11. Cressey TR, Urien S, Capparelli EV, Best B, Buranabanjasatean S, Limtrakul A, Rawangban B, Sabsanong P, Treluyer JM, Jourdain G, Stek A, Lallemant M, Mirochnick M. Impact of body weight and missed doses on lopinavir concentrations with standard and increased lopinavir/ritonavir doses during late pregnancy. J Antimicrob Chemother. 2015 Jan; 70(1):217-24. PMID: 25261418; PMCID: PMC4267507.
      12. Elder NM, Atayee RS, Best B, Ma JD. Authors' reply. J Anal Toxicol. 2014 Sep; 38(7):463. PMID: 24986838.
        View in: PubMed
      13. Jiang JY, Best B, Morello CM, Atayee RS, Ma JD. Evaluation of concomitant methylphenidate and opioid use in patients with pain. J Anal Toxicol. 2014 Sep; 38(7):421-6. PMID: 24907143.
        View in: PubMed
      14. Barakat NH, Atayee RS, Best B, Ma JD. Urinary hydrocodone and metabolite distributions in pain patients. J Anal Toxicol. 2014 Sep; 38(7):404-9. PMID: 24836897.
        View in: PubMed
      15. Mann LM, Atayee RS, Best B, Morello CM, Ma JD. Urine specimen detection of zolpidem use in patients with pain. J Anal Toxicol. 2014 Jul-Aug; 38(6):322-6. PMID: 24802157.
        View in: PubMed
      16. Cao JM, Ma JD, Morello CM, Atayee RS, Best B. Observations on hydrocodone and its metabolites in oral fluid specimens of the pain population: comparison with urine. J Opioid Manag. 2014 May-Jun; 10(3):177-86. PMID: 24944068.
        View in: PubMed
      17. Ramey K, Ma JD, Best B, Atayee RS, Morello CM. Variability in metabolism of imipramine and desipramine using urinary excretion data. J Anal Toxicol. 2014 Jul-Aug; 38(6):368-74. PMID: 24782142.
        View in: PubMed
      18. Liu JC, Ma JD, Morello CM, Atayee RS, Best B. Naltrexone metabolism and concomitant drug concentrations in chronic pain patients. J Anal Toxicol. 2014 May; 38(4):212-7. PMID: 24659754.
        View in: PubMed
      19. Yee DA, Hughes MM, Guo AY, Barakat NH, Tse SA, Ma JD, Best B, Atayee RS. Observation of improved adherence with frequent urine drug testing in patients with pain. J Opioid Manag. 2014 Mar-Apr; 10(2):111-8. PMID: 24715666.
        View in: PubMed
      20. McCormack SA, Best B. Obstetric Pharmacokinetic Dosing Studies are Urgently Needed. Front Pediatr. 2014; 2:9. PMID: 24575394; PMCID: PMC3920104.
      21. Elder NM, Atayee RS, Best B, Ma JD. Observations of urinary oxycodone and metabolite distributions in pain patients. J Anal Toxicol. 2014 Apr; 38(3):129-34. PMID: 24523296.
        View in: PubMed
      22. Luk S, Atayee RS, Ma JD, Best B. Urinary diazepam metabolite distribution in a chronic pain population. J Anal Toxicol. 2014 Apr; 38(3):135-42. PMID: 24500275.
        View in: PubMed
      23. Tse SA, Atayee RS, Ma JD, Best B. Factors affecting carisoprodol metabolism in pain patients using urinary excretion data. J Anal Toxicol. 2014 Apr; 38(3):122-8. PMID: 24488112.
        View in: PubMed
      24. Yee DA, Atayee RS, Best B, Ma JD. Observations on the urine metabolic profile of codeine in pain patients. J Anal Toxicol. 2014 Mar; 38(2):86-91. PMID: 24396053.
        View in: PubMed
      25. Moy KV, Ma JD, Morello CM, Atayee RS, Best B. Monitoring oxycodone use in patients with chronic pain: analysis of oxycodone and metabolite excretion in saliva and urine. J Opioid Manag. 2014 Jan-Feb; 10(1):47-56. PMID: 24604569.
        View in: PubMed
      26. Ellis RJ, Letendre S, Vaida F, Haubrich R, Heaton RK, Sacktor N, Clifford DB, Best B, May S, Umlauf A, Cherner M, Sanders C, Ballard C, Simpson DM, Jay C, McCutchan JA. Randomized trial of central nervous system-targeted antiretrovirals for HIV-associated neurocognitive disorder. Clin Infect Dis. 2014 Apr; 58(7):1015-22. PMID: 24352352; PMCID: PMC3952601.
      27. Morello CM, Neighbors M, Luu L, Kobayashi S, Mutrux B, Best B. Impact of a first-year student pharmacist diabetes self-care education program. Am J Pharm Educ. 2013 Dec 16; 77(10):215. PMID: 24371339; PMCID: PMC3872934.
      28. Bordson SJ, Atayee RS, Ma JD, Best B. Tricyclic antidepressants: is your patient taking them? Observations on adherence and unreported use using prescriber-reported medication lists and urine drug testing. Pain Med. 2014 Mar; 15(3):355-63. PMID: 24308804.
        View in: PubMed
      29. Moy KV, Ma JD, Best B, Atayee RS. Factors impacting variability of the urinary normeperidine-to-meperidine metabolic ratio in patients with chronic pain. J Anal Toxicol. 2014 Jan-Feb; 38(1):1-7. PMID: 24133175.
        View in: PubMed
      30. Guo AY, Ma JD, Best B, Atayee RS. Urine specimen detection of concurrent nonprescribed medicinal and illicit drug use in patients prescribed buprenorphine. J Anal Toxicol. 2013 Nov-Dec; 37(9):636-41. PMID: 24080973.
        View in: PubMed
      31. Cressey TR, Best B, Achalapong J, Stek A, Wang J, Chotivanich N, Yuthavisuthi P, Suriyachai P, Prommas S, Shapiro DE, Watts DH, Smith E, Capparelli E, Kreitchmann R, Mirochnick M. Reduced indinavir exposure during pregnancy. Br J Clin Pharmacol. 2013 Sep; 76(3):475-83. PMID: 23305215; PMCID: PMC3769674.
      32. Kreitchmann R, Best B, Wang J, Stek A, Caparelli E, Watts DH, Smith E, Shapiro DE, Rossi S, Burchett SK, Hawkins E, Byroads M, Cressey TR, Mirochnick M. Pharmacokinetics of an increased atazanavir dose with and without tenofovir during the third trimester of pregnancy. J Acquir Immune Defic Syndr. 2013 May 01; 63(1):59-66. PMID: 23392467; PMCID: PMC3625451.
      33. Nguyen A, Rossi S, Croteau D, Best B, Clifford D, Collier AC, Gelman B, Marra C, McArthur J, McCutchan JA, Morgello S, Simpson D, Ellis RJ, Grant I, Capparelli E, Letendre S. Etravirine in CSF is highly protein bound. J Antimicrob Chemother. 2013 May; 68(5):1161-8. PMID: 23335197; PMCID: PMC3625433.
      34. Croteau D, Rossi SS, Best B, Capparelli E, Ellis RJ, Clifford DB, Collier AC, Gelman BB, Marra CM, McArthur J, McCutchan JA, Morgello S, Simpson DM, Grant I, Letendre S. Darunavir is predominantly unbound to protein in cerebrospinal fluid and concentrations exceed the wild-type HIV-1 median 90% inhibitory concentration. J Antimicrob Chemother. 2013 Mar; 68(3):684-9. PMID: 23143899; PMCID: PMC3566670.
      35. Salo E, Griffiths EP, Farstad T, Schiller B, Nakamura Y, Yashiro M, Uehara R, Best B, Burns JC. Incidence of Kawasaki disease in northern European countries. Pediatr Int. 2012 Dec; 54(6):770-2. PMID: 22726311; PMCID: PMC3467350.
      36. Atayee RS, Singh RF, Best B, Freedman BA, Morello CM. An active-learning assignment involving peer-to-peer presentations to improve pharmacy students' attitudes and knowledge of dietary supplements. Am J Pharm Educ. 2012 Aug 10; 76(6):113. PMID: 22919089; PMCID: PMC3425928.
      37. Yaksh TL, de Kater A, Dean R, Best B, Miljanich GP. Pharmacokinetic analysis of ziconotide (SNX-111), an intrathecal N-type calcium channel blocking analgesic, delivered by bolus and infusion in the dog. Neuromodulation. 2012 Nov-Dec; 15(6):508-19; discussion 519. PMID: 22748108; PMCID: PMC3514653.
      38. Barakat NH, Atayee RS, Best B, Pesce AJ. Relationship between the concentration of hydrocodone and its conversion to hydromorphone in chronic pain patients using urinary excretion data. J Anal Toxicol. 2012 May; 36(4):257-64. PMID: 22511700.
        View in: PubMed
      39. Hughes MM, Atayee RS, Best B, Pesce AJ. Observations on the metabolism of morphine to hydromorphone in pain patients. J Anal Toxicol. 2012 May; 36(4):250-6. PMID: 22511699.
        View in: PubMed
      40. Leimanis E, Best B, Atayee RS, Pesce AJ. Evaluating the relationship of methadone concentrations and EDDP formation in chronic pain patients. J Anal Toxicol. 2012 May; 36(4):239-49. PMID: 22511698.
        View in: PubMed
      41. Yee DA, Best B, Atayee RS, Pesce AJ. Observations on the urine metabolic ratio of oxymorphone to oxycodone in pain patients. J Anal Toxicol. 2012 May; 36(4):232-8. PMID: 22511697.
        View in: PubMed
      42. Tse SA, Atayee RS, Best B, Pesce AJ. Evaluating the relationship between carisoprodol concentrations and meprobamate formation and inter-subject and intra-subject variability in urinary excretion data of pain patients. J Anal Toxicol. 2012 May; 36(4):221-31. PMID: 22511696.
        View in: PubMed
      43. Croteau D, Best B, Letendre S, Rossi SS, Ellis RJ, Clifford DB, Collier AC, Gelman BB, McArthur JC, McCutchan JA, Morgello S, Grant I. Lower than expected maraviroc concentrations in cerebrospinal fluid exceed the wild-type CC chemokine receptor 5-tropic HIV-1 50% inhibitory concentration. AIDS. 2012 Apr 24; 26(7):890-3. PMID: 22313954; PMCID: PMC3454507.
      44. Best B, Letendre SL, Koopmans P, Rossi SS, Clifford DB, Collier AC, Gelman BB, Marra CM, McArthur JC, McCutchan JA, Morgello S, Simpson DM, Capparelli EV, Ellis RJ, Grant I. Low cerebrospinal fluid concentrations of the nucleotide HIV reverse transcriptase inhibitor, tenofovir. J Acquir Immune Defic Syndr. 2012 Apr 01; 59(4):376-81. PMID: 22217676; PMCID: PMC3299895.
      45. Cressey TR, Stek A, Capparelli E, Bowonwatanuwong C, Prommas S, Sirivatanapa P, Yuthavisuthi P, Neungton C, Huo Y, Smith E, Best B, Mirochnick M. Efavirenz pharmacokinetics during the third trimester of pregnancy and postpartum. J Acquir Immune Defic Syndr. 2012 Mar 01; 59(3):245-52. PMID: 22083071; PMCID: PMC3288559.
      46. Croteau D, Letendre S, Best B, Rossi SS, Ellis RJ, Clifford DB, Collier AC, Gelman BB, Marra CM, McArthur J, McCutchan JA, Morgello S, Simpson DM, Way L, Capparelli E, Grant I. Therapeutic amprenavir concentrations in cerebrospinal fluid. Antimicrob Agents Chemother. 2012 Apr; 56(4):1985-9. PMID: 22290964; PMCID: PMC3318381.
      47. Best B, Capparelli EV, Diep H, Rossi SS, Farrell MJ, Williams E, Lee G, van den Anker JN, Rakhmanina N. Pharmacokinetics of lopinavir/ritonavir crushed versus whole tablets in children. J Acquir Immune Defic Syndr. 2011 Dec 01; 58(4):385-91. PMID: 21876444; PMCID: PMC3205189.
      48. Stek AM, Best B, Luo W, Capparelli E, Burchett S, Hu C, Li H, Read JS, Jennings A, Barr E, Smith E, Rossi SS, Mirochnick M. Effect of pregnancy on emtricitabine pharmacokinetics. HIV Med. 2012 Apr; 13(4):226-35. PMID: 22129166; PMCID: PMC3342997.
      49. Tremoulet AH, Devera G, Best B, Jimenez-Fernandez S, Sun X, Jain S, Burns JC. Increased incidence and severity of Kawasaki disease among Filipino-Americans in San Diego county. Pediatr Infect Dis J. 2011 Oct; 30(10):909-11. PMID: 21552184.
        View in: PubMed
      50. Sato YZ, Molkara DP, Daniels LB, Tremoulet AH, Shimizu C, Kanegaye JT, Best B, Snider JV, Frazer JR, Maisel A, Burns JC. Cardiovascular biomarkers in acute Kawasaki disease. Int J Cardiol. 2013 Mar 20; 164(1):58-63. PMID: 21777987; PMCID: PMC3253177.
      51. Mirochnick M, Best B, Stek AM, Capparelli EV, Hu C, Burchett SK, Rossi SS, Hawkins E, Basar M, Smith E, Read JS. Atazanavir pharmacokinetics with and without tenofovir during pregnancy. J Acquir Immune Defic Syndr. 2011 Apr 15; 56(5):412-9. PMID: 21283017; PMCID: PMC3125419.
      52. Hirsch JD, Gonzales M, Rosenquist A, Miller TA, Gilmer TP, Best B. Antiretroviral therapy adherence, medication use, and health care costs during 3 years of a community pharmacy medication therapy management program for Medi-Cal beneficiaries with HIV/AIDS. J Manag Care Pharm. 2011 Apr; 17(3):213-23. PMID: 21434698.
        View in: PubMed
      53. Rosenquist A, Best B, Miller TA, Gilmer TP, Hirsch JD. Medication therapy management services in community pharmacy: a pilot programme in HIV specialty pharmacies. J Eval Clin Pract. 2010 Dec; 16(6):1142-6. PMID: 21143346.
        View in: PubMed
      54. Mirochnick M, Best B, Clarke DF. Antiretroviral pharmacology: special issues regarding pregnant women and neonates. Clin Perinatol. 2010 Dec; 37(4):907-27, xi. PMID: 21078458.
        View in: PubMed
      55. Best B, Koopmans PP, Letendre SL, Capparelli EV, Rossi SS, Clifford DB, Collier AC, Gelman BB, Mbeo G, McCutchan JA, Simpson DM, Haubrich R, Ellis R, Grant I. Efavirenz concentrations in CSF exceed IC50 for wild-type HIV. J Antimicrob Chemother. 2011 Feb; 66(2):354-7. PMID: 21098541; PMCID: PMC3019085.
      56. Croteau D, Letendre S, Best B, Ellis RJ, Breidinger S, Clifford D, Collier A, Gelman B, Marra C, Mbeo G, McCutchan A, Morgello S, Simpson D, Way L, Vaida F, Ueland S, Capparelli E, Grant I. Total raltegravir concentrations in cerebrospinal fluid exceed the 50-percent inhibitory concentration for wild-type HIV-1. Antimicrob Agents Chemother. 2010 Dec; 54(12):5156-60. PMID: 20876368; PMCID: PMC2981289.
      57. Best B, Stek AM, Mirochnick M, Hu C, Li H, Burchett SK, Rossi SS, Smith E, Read JS, Capparelli EV. Lopinavir tablet pharmacokinetics with an increased dose during pregnancy. J Acquir Immune Defic Syndr. 2010 Aug; 54(4):381-8. PMID: 20632458; PMCID: PMC3265163.
      58. Fury W, Tremoulet AH, Watson VE, Best B, Shimizu C, Hamilton J, Kanegaye JT, Wei Y, Kao C, Mellis S, Lin C, Burns JC. Transcript abundance patterns in Kawasaki disease patients with intravenous immunoglobulin resistance. Hum Immunol. 2010 Sep; 71(9):865-73. PMID: 20600450; PMCID: PMC2929310.
      59. Morello CM, Singh RF, Chen KJ, Best B. Enhancing an introductory Pharmacy Practice Experience at free medical clinics. Int J Pharm Pract. 2010 Feb; 18(1):51-7. PMID: 20405596.
        View in: PubMed
      60. Cole JM, Best B, Pesce AJ. Variability of transdermal fentanyl metabolism and excretion in pain patients. J Opioid Manag. 2010 Jan-Feb; 6(1):29-39. PMID: 20297612.
        View in: PubMed
      61. Aweeka FT, Stek A, Best B, Hu C, Holland D, Hermes A, Burchett SK, Read J, Mirochnick M, Capparelli EV. Lopinavir protein binding in HIV-1-infected pregnant women. HIV Med. 2010 Apr; 11(4):232-8. PMID: 20002783; PMCID: PMC2874627.
      62. Koopmans PP, Ellis R, Best B, Letendre S. Should antiretroviral therapy for HIV infection be tailored for intracerebral penetration? Neth J Med. 2009 Jun; 67(6):206-11. PMID: 19749389.
        View in: PubMed
      63. Wang S, Best B, Burns JC. Periungual desquamation in patients with Kawasaki disease. Pediatr Infect Dis J. 2009 Jun; 28(6):538-9. PMID: 19483521; PMCID: PMC2738931.
      64. Kanegaye JT, Wilder MS, Molkara D, Frazer JR, Pancheri J, Tremoulet AH, Watson VE, Best B, Burns JC. Recognition of a Kawasaki disease shock syndrome. Pediatrics. 2009 May; 123(5):e783-9. PMID: 19403470; PMCID: PMC2848476.
      65. Shike H, Kanegaye JT, Best B, Pancheri J, Burns JC. Pyuria associated with acute Kawasaki disease and fever from other causes. Pediatr Infect Dis J. 2009 May; 28(5):440-3. PMID: 19319019; PMCID: PMC2738928.
      66. Best B, Letendre SL, Brigid E, Clifford DB, Collier AC, Gelman BB, McArthur JC, McCutchan JA, Simpson DM, Ellis R, Capparelli EV, Grant I. Low atazanavir concentrations in cerebrospinal fluid. AIDS. 2009 Jan 02; 23(1):83-7. PMID: 19050389; PMCID: PMC2642983.
      67. Hirsch JD, Rosenquist A, Best B, Miller TA, Gilmer TP. Evaluation of the first year of a pilot program in community pharmacy: HIV/AIDS medication therapy management for Medi-Cal beneficiaries. J Manag Care Pharm. 2009 Jan-Feb; 15(1):32-41. PMID: 19125548.
        View in: PubMed
      68. Mirochnick M, Best B, Stek AM, Capparelli E, Hu C, Burchett SK, Holland DT, Smith E, Gaddipati S, Read JS. Lopinavir exposure with an increased dose during pregnancy. J Acquir Immune Defic Syndr. 2008 Dec 15; 49(5):485-91. PMID: 18989231; PMCID: PMC3912695.
      69. Atayee RS, Best B, Daniels CE. Development of an ambulatory palliative care pharmacist practice. J Palliat Med. 2008 Oct; 11(8):1077-82. PMID: 18980446.
        View in: PubMed
      70. Read JS, Best B, Stek AM, Hu C, Capparelli EV, Holland DT, Burchett SK, Smith ME, Sheeran EC, Shearer WT, Febo I, Mirochnick M. Pharmacokinetics of new 625 mg nelfinavir formulation during pregnancy and postpartum. HIV Med. 2008 Nov; 9(10):875-82. PMID: 18795962; PMCID: PMC2732353.
      71. Burns JC, Best B, Mejias A, Mahony L, Fixler DE, Jafri HS, Melish ME, Jackson MA, Asmar BI, Lang DJ, Connor JD, Capparelli EV, Keen ML, Mamun K, Keenan GF, Ramilo O. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. J Pediatr. 2008 Dec; 153(6):833-8. PMID: 18672254; PMCID: PMC2856847.
      72. Best B, Goicoechea M. Efavirenz--still first-line king? Expert Opin Drug Metab Toxicol. 2008 Jul; 4(7):965-72. PMID: 18624683.
        View in: PubMed
      73. Best B, Capparelli EV. Implications of gender and pregnancy for antiretroviral drug dosing. Curr Opin HIV AIDS. 2008 May; 3(3):277-82. PMID: 19372979; PMCID: PMC2804899.
      74. Capparelli EV, Aweeka F, Hitti J, Stek A, Hu C, Burchett SK, Best B, Smith E, Read JS, Watts H, Nachman S, Thorpe EM, Spector SA, Jimenez E, Shearer WT, Foca M, Mirochnick M. Chronic administration of nevirapine during pregnancy: impact of pregnancy on pharmacokinetics. HIV Med. 2008 Apr; 9(4):214-20. PMID: 18366444; PMCID: PMC2755564.
      75. Tremoulet AH, Best B, Song S, Wang S, Corinaldesi E, Eichenfield JR, Martin DD, Newburger JW, Burns JC. Resistance to intravenous immunoglobulin in children with Kawasaki disease. J Pediatr. 2008 Jul; 153(1):117-21. PMID: 18571548; PMCID: PMC2526555.
      76. Letendre S, Marquie-Beck J, Capparelli E, Best B, Clifford D, Collier AC, Gelman BB, McArthur JC, McCutchan JA, Morgello S, Simpson D, Grant I, Ellis RJ. Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol. 2008 Jan; 65(1):65-70. PMID: 18195140; PMCID: PMC2763187.
      77. Goicoechea M, Liu S, Best B, Sun S, Jain S, Kemper C, Witt M, Diamond C, Haubrich R, Louie S. Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy. J Infect Dis. 2008 Jan 01; 197(1):102-8. PMID: 18171292.
        View in: PubMed
      78. Best B, Goicoechea M, Witt MD, Miller L, Daar ES, Diamond C, Tilles JG, Kemper CA, Larsen R, Holland DT, Sun S, Jain S, Wagner G, Capparelli EV, McCutchan JA, Haubrich RH. A randomized controlled trial of therapeutic drug monitoring in treatment-naive and -experienced HIV-1-infected patients. J Acquir Immune Defic Syndr. 2007 Dec 01; 46(4):433-42. PMID: 17786128.
        View in: PubMed
      79. Goicoechea M, Best B. Efavirenz/emtricitabine/tenofovir disoproxil fumarate fixed-dose combination: first-line therapy for all? Expert Opin Pharmacother. 2007 Feb; 8(3):371-82. PMID: 17266471.
        View in: PubMed
      80. Letendre SL, Marquie-Beck J, Ellis RJ, Woods SP, Best B, Clifford DB, Collier AC, Gelman BB, Marra C, McArthur JC, McCutchan JA, Morgello S, Simpson D, Alexander TJ, Durelle J, Heaton R, Grant I. The role of cohort studies in drug development: clinical evidence of antiviral activity of serotonin reuptake inhibitors and HMG-CoA reductase inhibitors in the central nervous system. J Neuroimmune Pharmacol. 2007 Mar; 2(1):120-7. PMID: 18040835.
        View in: PubMed
      81. Goicoechea M, Best B, Capparelli E, Caperna J, Ballard C, Haubrich R. Therapeutic ritonavir-boosted atazanavir plasma concentration and concurrent omeprazole use. AIDS. 2006 Oct 24; 20(16):2127-8. PMID: 17053363.
        View in: PubMed
      82. Stek AM, Mirochnick M, Capparelli E, Best B, Hu C, Burchett SK, Elgie C, Holland DT, Smith E, Tuomala R, Cotter A, Read JS. Reduced lopinavir exposure during pregnancy. AIDS. 2006 Oct 03; 20(15):1931-9. PMID: 16988514.
        View in: PubMed
      83. Goicoechea M, Best B, Capparelli E, Haubrich R. Concurrent use of efavirenz and oxcarbazepine may not affect efavirenz plasma concentrations. Clin Infect Dis. 2006 Jul 01; 43(1):116-7. PMID: 16758435.
        View in: PubMed
      84. Goicoechea M, Best B, Seefried E, Wagner G, Capparelli E, Haubrich R. Failure of modified directly observed therapy combined with therapeutic drug monitoring to enhance antiretroviral adherence in a patient with major depression. AIDS Patient Care STDS. 2006 Apr; 20(4):233-7. PMID: 16623621.
        View in: PubMed
      85. Best B, Mirochnick M, Capparelli EV, Stek A, Burchett SK, Holland DT, Read JS, Smith E, Hu C, Spector SA, Connor JD. Impact of pregnancy on abacavir pharmacokinetics. AIDS. 2006 Feb 28; 20(4):553-60. PMID: 16470119.
        View in: PubMed
      86. Best B, Haubrich R. Tipranavir: a protease inhibitor for multi-drug resistant HIV-1. Expert Opin Investig Drugs. 2006 Jan; 15(1):59-70. PMID: 16370934.
        View in: PubMed
      87. Best B, Burns JC, DeVincenzo J, Phelps SJ, Blumer JL, Wilson JT, Capparelli EV, Connor JD. Pharmacokinetic and tolerability assessment of a pediatric oral formulation of pentoxifylline in kawasaki disease. Curr Ther Res Clin Exp. 2003 Feb; 64(2):96-115. PMID: 24944359; PMCID: PMC4053025.